IQVIA (NYSE:IQV) Shares Acquired Sen. Markwayne Mullin

Senator Markwayne Mullin (R-Oklahoma) recently bought shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on February 27th, the Senator disclosed that they had bought between $15,001 and $50,000 in IQVIA stock on February 13th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Honeywell International (NASDAQ:HON) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Brick (TSE:BRK) on 2/13/2025.
• Sold $100,001 – $250,000 in shares of Vanguard Materials ETF (NYSEARCA:VAW) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of Microsoft (NASDAQ:MSFT) on 2/13/2025.
• Sold $15,001 – $50,000 in shares of Constellation Brands (NYSE:STZ) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of LPL Financial (NASDAQ:LPLA) on 2/13/2025.
• Purchased $15,001 – $50,000 in shares of TJX Companies (NYSE:TJX) on 2/13/2025.
• Sold $50,001 – $100,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 2/13/2025.
• Purchased $50,001 – $100,000 in shares of Accenture (NYSE:ACN) on 2/13/2025.

IQVIA Stock Performance

IQV stock opened at $186.40 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a 50 day moving average price of $199.30 and a 200 day moving average price of $215.26. IQVIA Holdings Inc. has a fifty-two week low of $184.66 and a fifty-two week high of $261.73. The stock has a market capitalization of $32.82 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the transaction, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after purchasing an additional 105,504 shares during the period. Canada Pension Plan Investment Board boosted its stake in IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after purchasing an additional 712,958 shares during the period. Geode Capital Management LLC boosted its stake in IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock worth $818,315,000 after purchasing an additional 77,981 shares during the period. FMR LLC boosted its stake in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. Finally, Invesco Ltd. boosted its stake in IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock worth $509,012,000 after purchasing an additional 902,226 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on IQV shares. Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, Robert W. Baird lowered their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.